ZOVIRAX is the brand name for acyclovir, a synthetic nucleoside analog active against herpesviruses. Acyclovir sodium for injection is a sterile lyophilized powder for intravenous administration only.
Herpes Simplex Infections in Immunocompromised Patients: ZOVIRAX for Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients.
Initial Episodes of Herpes Genitalis: ZOVIRAX for Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients.
Herpes Simplex Encephalitis: ZOVIRAX for Injection is indicated for the treatment of herpes simplex encephalitis.
Neonatal Herpes Simplex Virus Infection: ZOVIRAX for Injection is indicated for the treatment of neonatal herpes infections.
Varicella-Zoster Infections in Immunocompromised Patients: ZOVIRAX for Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients.
Published Studies Related to Zovirax Injection (Acyclovir)
ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo-
and valacyclovir-controlled, dose-finding study. 
replication... CONCLUSIONS: Three-day or single-day courses of ASP2151 appear to be effective
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels
during pregnancy and postpartum: a randomized trial. 
mother-to-child transmission (PMTCT) interventions is unknown... CONCLUSIONS: Valacyclovir significantly decreased early breast milk and plasma
Oral acyclovir suppression and neurodevelopment after neonatal herpes. [2011.10.06]
BACKGROUND: Poor neurodevelopmental outcomes and recurrences of cutaneous lesions remain unacceptably frequent among survivors of neonatal herpes simplex virus (HSV) disease... CONCLUSIONS: Infants surviving neonatal HSV disease with CNS involvement had improved neurodevelopmental outcomes when they received suppressive therapy with oral acyclovir for 6 months. (Funded by the National Institute of Allergy and Infectious Diseases; CASG 103 and CASG 104 ClinicalTrials.gov numbers, NCT00031460 and NCT00031447, respectively.).
The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women. [2011.10]
Herpes simplex virus (HSV) infections are ubiquitous in humans, but the determinants of clinical and virologic severity are not completely understood.
Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania. [2011.08]
OBJECTIVES: Few studies have examined the frequency and duration of genital herpes simplex virus (HSV) shedding in sub-Saharan Africa. This study describes HSV shedding patterns among a sample of HSV-2-seropositive women enrolled in a placebo-controlled trial of HSV suppressive therapy (acyclovir 400 mg twice a day) in Tanzania... CONCLUSIONS: HSV shedding was common, varying greatly by individual. Shedding rates were similar to studies in African and non-African settings. Among HIV-negative women, shedding rates were lower in the acyclovir arm; however, acyclovir did not substantially impact on HSV shedding in HIV-positive women.
Clinical Trials Related to Zovirax Injection (Acyclovir)
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo) [Recruiting]
Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in babies.
Appropriate dosing of acyclovir is known for adults and children but acyclovir has not been
adequately studied in full-term or premature neonates. HSV is a very serious infection in
babies <6 months of age and often results in death or profound mental retardation. HSV
leads to profound mental retardation in young infants because the virus attacks the central
The investigators hypothesize that the currently recommended dose of acyclovir is inadequate
to produce adequate blood levels to combat herpes simplex infection. The investigators
propose to study acyclovir levels in the blood of babies who are placed on acyclovir to
treat a suspected HSV infection. This will allow them to determine the appropriate dose in
premature infants. This is an unmet public health need because it is likely that the drug
behaves differently in premature infants than it does in term infants and older children.
Premature babies have more body water and less body tissue. Their kidneys are more immature
and do not function as well as full term infants. Premature neonates are also at the
greatest risk from herpes infection because they have poorly functioning immature immune
systems. Early and appropriate treatment with acyclovir has resulted in improved outcome in
Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS) [Completed]
To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303
gel in combination with acyclovir, relative to acyclovir alone, for the treatment of
recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and
neighboring areas, in patients with AIDS.
Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease [Recruiting]
Meniere's disease is a chronic illness that affects a substantial number of patients every
year worldwide. The disease is characterized by intermittent episodes of vertigo lasting
from minutes to hours, with fluctuating sensorineural hearing loss, tinnitus, and aural
pressure. It has recently been suggested that viral etiologies specially Herpes virus might
be the underlying reason. The investigators study is a randomized, double- blinded
placebo-controlled clinical trial in Amiralam Hospital. In this study the primary objective
is to assess efficacy of Acyclovir in control of symptoms in patients with Meniere's disease
specially their vertigo attacks. Inclusion criteria would be patient's willingness to
participate in the study and follow ups, being 18 years old or older, having at least 2
vertigos per month each at least 20 min, interfering with function, and not on medication
for Meniere's disease for at least 3 months before the trial. They should not have any
history of allergy to Acyclovir, renal insufficiency or Creatinine above 1. 5 mg/dl, hepatic
enzymes more than three times normal, serious uncontrolled illness, be pregnant or nursing
or have previous surgeries on Endolymphatic Sac. Participants will be randomly placed in 2
different arms getting either Acyclovir 400 mg or placebo (inert ingredient). They will take
the medication for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a
day for the last 10 days. Patients will report changes in their symptoms 10 days after
initiating the drug and in 1, 3, 6 month intervals.
Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2) [Recruiting]
The purpose of this study is to determine whether acyclovir is effective in suppressing HIV
viral load in women infected with both HIV-1 and herpes simplex virus type 2 (HSV-2) who are
starting HIV treatment for the first time.
Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC) [Recruiting]